Patent intelligence · US
US 7022725
Isoxazole derivatives
Isoxazole derivatives
Patent details — US 7022725
- Jurisdiction
- US
- Status
- expired
- Grant date
- Apr 4, 2006
- Expiration
- Mar 30, 2026
- Applicant
- Takeda Pharmaceutical Company Limited
- Claims
- 14
- CPC classes
- A61K, A61K31/42, A61K31/427, A61K31/454
Quick answer
US 7022725 (Isoxazole derivatives) is held by Takeda Pharmaceutical Company Limited. Status: expired. Granted Apr 4, 2006. Expires Mar 30, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/42, A61K31/427, A61K31/454, A61K31/4709, A61K31/496
More from Takeda Pharmaceutical Company Limited
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 7022725?
US 7022725 (Isoxazole derivatives) is held by Takeda Pharmaceutical Company Limited. Status: expired. Granted Apr 4, 2006. Expires Mar 30, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7022725?
Takeda Pharmaceutical Company Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 7022725 expire?
Our index shows an expiration date of Mar 30, 2026 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.